Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06807268 · ClinicalTrials.gov registry record · Phase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
A Phase 3 study of Eczema, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06807268 is a Phase 3 study of Eczema that is actively recruiting participants, run by Pfizer. The registered enrollment target is 150 participants, below the 201-participant average among 29 other Eczema trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT06807268, a Phase 3 study of Eczema, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Abrocitinib
Study Locations (20)
California
- Investigational Drug Service - Rady Childrens Hospital-San Diego - San Diego
- University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm - San Diego
South Carolina
- Medical University of South Carolina - Charleston
- Tribe Clinical Research, LLC - Greenville
Other
- Shanghai Children's Hospital - Shanghai
- Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine - Shanghai
Alabama
- Cahaba Dermatology & Skin Health Center, LLC - Birmingham
Arkansas
- Arkansas Research Trials - North Little Rock
Florida
- Solutions Through Advanced Research - Jacksonville
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Missouri
- Saint Louis University - Department of Dermatology - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-07-24 |
| Est. Completion | 2027-05-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06807268
The ClinicalTrials.gov registry entry for NCT06807268 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 29 other Eczema trials with a reported enrollment target (25% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eczema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06807268 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, South Carolina, Other.
Frequently Asked Questions
What is clinical trial NCT06807268 about?
NCT06807268 is a clinical study titled "A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema". This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to re...
What is the current status of trial NCT06807268?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2025-07-24. Estimated completion is 2027-05-02.
What conditions does trial NCT06807268 study?
This clinical trial studies the following conditions: Eczema.
What interventions are being tested in trial NCT06807268?
The interventions under investigation include: Placebo (OTHER), Abrocitinib (DRUG).
Who is sponsoring clinical trial NCT06807268?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06807268 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eczema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.